Researchers at University of California San Diego School of Medicine found in a mouse model that when fed a Western diet rich in calories, fat and cholesterol, the mice progressively became obese, diabetic and developed NASH, which progressed to HCC, chronic kidney and cardiovascular disease.
Immunotherapy is not only significantly less effective in liver cancer patients who previously had a liver disease called non-alcoholic steatohepatitis (NASH), but actually appears to fuel tumor growth, according to a Mount Sinai study published in Nature in March. NASH affects as many as 40 million people worldwide and is associated with obesity and diabetes.
To help develop the latest treatment methods and expand cancer care service, Thomas Daniels, MD, has been appointed service chief of the Department of Radiation Oncology at Perlmutter Cancer Center–Sunset Park in Brooklyn.
Article title: AICAR and Compound C negatively modulate HCC-induced primary human hepatic stellate cell activation in vitro Authors: Katrin Böttcher, Lisa Longato, Giusi Marrone, Giuseppe Mazza, Leo Ghemtio, Andrew Hall, Tu Vinh Luong, Stefano Caruso, Benoit Viollet, Jessica Zucman-Rossi, Massimo…
Early detection could reduce the number of African Americans dying from liver cancer, but current screening guidelines may not find cancer soon enough in this community, according to a study published in Cancer in February.
A Mayo Clinic team, led by Rahmi Oklu, M.D., Ph.D., a vascular and interventional radiologist at Mayo Clinic, in collaboration with Samir Mitragotri, Ph.D., of Harvard University, report the development of a new ionic liquid formulation that killed cancer cells and allowed uniform distribution of a chemotherapy drug into liver tumors and other solid tumors in the lab.
Article title: Global changes to HepG2 cell metabolism in response to galactose treatment Authors: Robert A. Skolik, Jason Solocinski, Mary E. Konkle, Nilay Chakraborty, Michael A. Menze From the authors: “Here we demonstrate that the metabolic poise in tumor-derived HepG2 cells…
Researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine are collaborating with faculty at the University of Pennsylvania to develop a risk score that more comprehensively prioritizes liver cancer patients for transplantation.
Bursting gas-filled microbubbles using ultrasound waves sensitizes tumors to targeted radiation, reducing tumor growth and improving overall survival after treatment.
University of Miami Miller School of Medicine and Emory researchers found significant differences in death rates even within the same state, according to a recently published study in Gastroenterology.
Hepatitis B disproportionately impacts U.S. Blacks, including African American and Haitian Blacks. Both communities suffer from widespread misinformation and access to care issues that might avert disease detection and prevention, according to a study published in Cancer Causes & Control by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.
Incidence and mortality of hepatocellular carcinoma (HCC), a common type of liver cancer, is increasing in the United States. Rutgers Cancer Institute of New Jersey experts have received a $50,000 award through the Translational Research Pilot Award Program that will support the examination of how a drug combination impacts the growth of both human HCC cancer cells and tumors in laboratory models, with the goal of identifying a new treatment for patients with this disease.
A biomedical engineering research team from Tulane University is developing a novel cancer treatment hepatocellular carcinoma, a highly fatal form of liver cancer.
UCAL researchers are developing a nanotechnology-enabled cancer diagnostic solution that will help detect early stage liver cancer for people who are at risk of developing the disease.
Article title: Experimental analysis of T cell epitopes for designing liver cancer vaccine predicted by system-level immunoinformatics approach Authors: Syed Aun Muhammad, Sidra Zafar, Samana Zahra Rizvi, Imran Imran, Fahad Munir, Muhammad Babar Jamshed, Amjad Ali, Xiaogang Wu, Numan Shahid,…
A first-in-class clinical trial suggests a novel treatment measurably slowed progression of non-alcoholic fatty liver disease to its more progressive and deadly form.
“Senotherapy,” a treatment that uses small molecule drugs to target “senescent” cells, or those cells that no longer undergo cell division, blunts liver tumor progression in animal models according to new research from a team led by Celeste Simon, PhD, a professor of Cell and Developmental Biology in the Perelman School of Medicine at the University of Pennsylvania and scientific director of the Abramson Family Cancer Research Institute. The study was published in Nature Cell Biology.
For the first time in over a decade, scientists have identified a first-line treatment that significantly improves survival for people with hepatocellular carcinoma, the most common type of liver cancer.
A study explored racial inequalities in death from liver cancer before and after the introduction of lifesaving drugs for hepatitis C. Results showed that from 1979 to 1998, racial inequalities in mortality from liver cancer in the U.S. were declining. But, from 1998 to 2016, of the 16,770 deaths from liver cancer among blacks, the excess relative to whites increased from 27.8 percent to 45.4 percent. Concurrently, racial inequalities in death decreased for major risk factors for liver cancer, such as alcohol and diabetes.
Researchers from the UCLA Jonsson Comprehensive Cancer Center received a $2.8 million, five-year grant from the National Cancer Institute to help develop a blood-based test to improve the selection and prioritization for patients with liver cancer who need a liver transplantation.
A diagnosis of pancreatic or colon cancer often sparks dread about the disease’s likely next destination: the liver. That’s because liver metastasis is a leading cause of death in these patients. A Cedars-Sinai scientific team has been awarded a $9.1 million grant by the National Cancer Institute to study this often-fatal process, with the goal of understanding how cancer spreads to the liver and finding ways to block it.
Mice given a new drug targeting a key gene involved in lipid and glucose metabolism could tolerate a high-fat diet regimen (composed of 60% fat from lard) without developing significant liver damage, becoming obese, or disrupting their body’s glucose balance.
Many liver cancer tumors contain a highly diverse set of cells, a phenomenon known as intra-tumor heterogeneity that can significantly affect the rate at which the cancer grows, Mount Sinai researchers report. The immune system’s contribution to this heterogeneity can have major clinical implications.
University of California San Diego School of Medicine and Moores Cancer Center researchers developed a math equation to predict and detect liver cancer and identified when healthy cells become cancerous.
Naturally occurring chemicals in the global food supply are known to pose a burden on worldwide health. New studies have found that a certain foodborne toxin, in addition to its known health effects,, is also linked to vaccine resistance, and for the first time the global burden of disease from foodborne arsenic, lead, cadmium, and methyl mercury has been quantified.. The Society for Risk Analysis (SRA) will present new studies as part of its Global Disease Burden Caused by Foodborne Chemicals and Toxins symposium on Monday, Dec. 9 from 1:30-3:00 p.m. as part of its 2019 Annual Meeting at the Crystal Gateway Marriott in Arlington, Virginia. This symposium will provide updates to a 2015 World Health Organization (WHO) publication which analyzed the disease burdens caused by these toxins.
Two new studies support and inform the use of proton radiation therapy to treat patients with hepatocellular carcinoma (HCC), a common but often fatal type of liver cancer for which there are limited treatment options. The studies were published in the International Journal of Radiation Oncology • Biology • Physics, the flagship scientific journal of the American Society for Radiation Oncology (ASTRO).
Disrupting a metabolic pathway in the liver in a way that creates a more “cancer-like” metabolism actually reduces tumor formation in a mouse model of liver cancer. This surprising finding from a Univ. of Iowa study identifies the mitochondrial pyruvate carrier as a potential target for preventing liver cancer.